Hearing Improvement After Bevacizumab in Patients with Neurofibromatosis Type 2

Overview

Journal N Engl J Med

Specialty General Medicine

Date 2009 Jul 10

PMID 19587327

Citations 192

Authors

Scott R Plotkin

Anat O Stemmer-Rachamimov

Fred G Barker 2nd

Chris Halpin

Timothy P Padera

Alex Tyrrell

A Gregory Sorensen

Rakesh K Jain

Emmanuelle di Tomaso

Affiliations

Soon will be listed here.

Abstract

Background: Profound hearing loss is a serious complication of neurofibromatosis type 2, a genetic condition associated with bilateral vestibular schwannomas, benign tumors that arise from the eighth cranial nerve. There is no medical treatment for such tumors.

Methods: We determined the expression pattern of vascular endothelial growth factor (VEGF) and three of its receptors, VEGFR-2, neuropilin-1, and neuropilin-2, in paraffin-embedded samples from 21 vestibular schwannomas associated with neurofibromatosis type 2 and from 22 sporadic schwannomas. Ten consecutive patients with neurofibromatosis type 2 and progressive vestibular schwannomas who were not candidates for standard treatment were treated with bevacizumab, an anti-VEGF monoclonal antibody. An imaging response was defined as a decrease of at least 20% in tumor volume, as compared with baseline. A hearing response was defined as a significant increase in the word-recognition score, as compared with baseline.

Results: VEGF was expressed in 100% of vestibular schwannomas and VEGFR-2 in 32% of tumor vessels on immunohistochemical analysis. Before treatment, the median annual volumetric growth rate for 10 index tumors was 62%. After bevacizumab treatment in the 10 patients, tumors shrank in 9 patients, and 6 patients had an imaging response, which was maintained in 4 patients during 11 to 16 months of follow-up. The median best response to treatment was a volumetric reduction of 26%. Three patients were not eligible for a hearing response; of the remaining seven patients, four had a hearing response, two had stable hearing, and one had progressive hearing loss. There were 21 adverse events of grade 1 or 2.

Conclusions: VEGF blockade with bevacizumab improved hearing in some, but not all, patients with neurofibromatosis type 2 and was associated with a reduction in the volume of most growing vestibular schwannomas.

Citing Articles

Efficacy and Toxicity of Bevacizumab in Children with NF2-Related Schwannomatosis: A Systematic Review.

Tops A, Schopman J, Koot R, Gelderblom H, Putri N, Rahmi L Cancers (Basel). 2025; 17(3).

PMID: 39941885 PMC: 11817438. DOI: 10.3390/cancers17030519.

Optimal Delivery of Pain Management in Schwannomatosis: A Literature Review.

Hino U, Tamura R, Toda M Ther Clin Risk Manag. 2025; 21():61-68.

PMID: 39839825 PMC: 11748755. DOI: 10.2147/TCRM.S362794.

Bevacizumab for Vestibular Schwannomas in Neurofibromatosis Type 2: A Systematic Review of Tumor Control and Hearing Preservation.

Screnci M, Puechmaille M, Berton Q, Khalil T, Mom T, Coll G J Clin Med. 2024; 13(23).

PMID: 39685944 PMC: 11642482. DOI: 10.3390/jcm13237488.

Alternatively activated macrophages are associated with faster growth rate in vestibular schwannoma.

Gregory G, Haley M, Jones A, Hannan C, Evans D, King A Brain Commun. 2024; 6(6):fcae400.

PMID: 39611183 PMC: 11604085. DOI: 10.1093/braincomms/fcae400.

Application of bevacizumab in the management of meningiomas: a systematic review and meta-analysis.

Hajikarimloo B, Hasanzade A, Sabbagh Alvani M, Habibi M Neurosurg Rev. 2024; 47(1):692.

PMID: 39327340 DOI: 10.1007/s10143-024-02889-w.

References

Caye-Thomasen P, Dethloff T, Hansen S, Stangerup S, Thomsen J . Hearing in patients with intracanalicular vestibular schwannomas. Audiol Neurootol. 2006; 12(1):1-12. DOI: 10.1159/000096152. View

Mulvihill J, Parry D, Sherman J, Pikus A, Eldridge R . NIH conference. Neurofibromatosis 1 (Recklinghausen disease) and neurofibromatosis 2 (bilateral acoustic neurofibromatosis). An update. Ann Intern Med. 1990; 113(1):39-52. DOI: 10.7326/0003-4819-113-1-39. View

Brieger J, Bedavanija A, Lehr H, Maurer J, Mann W . Expression of angiogenic growth factors in acoustic neurinoma. Acta Otolaryngol. 2004; 123(9):1040-5. DOI: 10.1080/00016480310005101. View

Caye-Thomasen P, Werther K, Nalla A, Bog-Hansen T, Nielsen H, Stangerup S . VEGF and VEGF receptor-1 concentration in vestibular schwannoma homogenates correlates to tumor growth rate. Otol Neurotol. 2005; 26(1):98-101. DOI: 10.1097/00129492-200501000-00017. View

Combs S, Volk S, Schulz-Ertner D, Huber P, Thilmann C, Debus J . Management of acoustic neuromas with fractionated stereotactic radiotherapy (FSRT): long-term results in 106 patients treated in a single institution. Int J Radiat Oncol Biol Phys. 2005; 63(1):75-81. DOI: 10.1016/j.ijrobp.2005.01.055. View

Babovic-Vuksanovic D, Ballman K, Michels V, McGrann P, Lindor N, King B . Phase II trial of pirfenidone in adults with neurofibromatosis type 1. Neurology. 2006; 67(10):1860-2. DOI: 10.1212/01.wnl.0000243231.12248.67. View

Flickinger J, Kondziolka D, Niranjan A, Lunsford L . Results of acoustic neuroma radiosurgery: an analysis of 5 years' experience using current methods. J Neurosurg. 2001; 94(1):1-6. DOI: 10.3171/jns.2001.94.1.0001. View

Halpin C, Rauch S . Using audiometric thresholds and word recognition in a treatment study. Otol Neurotol. 2005; 27(1):110-6. DOI: 10.1097/00129492-200601000-00020. View

Saito K, Kato M, Susaki N, Nagatani T, Nagasaka T, Yoshida J . Expression of Ki-67 antigen and vascular endothelial growth factor in sporadic and neurofibromatosis type 2-associated schwannomas. Clin Neuropathol. 2003; 22(1):30-4. View

10.

Plotkin S, Halpin C, Blakeley J, Slattery 3rd W, Welling D, Chang S . Suggested response criteria for phase II antitumor drug studies for neurofibromatosis type 2 related vestibular schwannoma. J Neurooncol. 2009; 93(1):61-77. PMC: 4036446. DOI: 10.1007/s11060-009-9867-7. View

11.

Uesaka T, Shono T, Suzuki S, Nakamizo A, Niiro H, Mizoguchi M . Expression of VEGF and its receptor genes in intracranial schwannomas. J Neurooncol. 2007; 83(3):259-66. DOI: 10.1007/s11060-007-9336-0. View

12.

Kamoun W, Ley C, Farrar C, Duyverman A, Lahdenranta J, Lacorre D . Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice. J Clin Oncol. 2009; 27(15):2542-52. PMC: 2739611. DOI: 10.1200/JCO.2008.19.9356. View

13.

Babovic-Vuksanovic D, Widemann B, Dombi E, Gillespie A, Wolters P, Toledo-Tamula M . Phase I trial of pirfenidone in children with neurofibromatosis 1 and plexiform neurofibromas. Pediatr Neurol. 2007; 36(5):293-300. DOI: 10.1016/j.pediatrneurol.2007.01.009. View

14.

Jain R . Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 2005; 307(5706):58-62. DOI: 10.1126/science.1104819. View

15.

Plotkin S, Singh M, ODonnell C, Harris G, McClatchey A, Halpin C . Audiologic and radiographic response of NF2-related vestibular schwannoma to erlotinib therapy. Nat Clin Pract Oncol. 2008; 5(8):487-91. DOI: 10.1038/ncponc1157. View

16.

Batchelor T, Sorensen A, Tomaso E, Zhang W, Duda D, Cohen K . AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell. 2007; 11(1):83-95. PMC: 2748664. DOI: 10.1016/j.ccr.2006.11.021. View

17.

Evans D, Moran A, King A, Saeed S, Gurusinghe N, Ramsden R . Incidence of vestibular schwannoma and neurofibromatosis 2 in the North West of England over a 10-year period: higher incidence than previously thought. Otol Neurotol. 2005; 26(1):93-7. DOI: 10.1097/00129492-200501000-00016. View

18.

Caye-Thomasen P, Baandrup L, Jacobsen G, Thomsen J, Stangerup S . Immunohistochemical demonstration of vascular endothelial growth factor in vestibular schwannomas correlates to tumor growth rate. Laryngoscope. 2003; 113(12):2129-34. DOI: 10.1097/00005537-200312000-00014. View

19.

Thornton A, Raffin M . Speech-discrimination scores modeled as a binomial variable. J Speech Hear Res. 1978; 21(3):507-18. DOI: 10.1044/jshr.2103.507. View

20.

Samii M, Gerganov V, Samii A . Improved preservation of hearing and facial nerve function in vestibular schwannoma surgery via the retrosigmoid approach in a series of 200 patients. J Neurosurg. 2006; 105(4):527-35. DOI: 10.3171/jns.2006.105.4.527. View